DUBLIN--(BUSINESS WIRE)--The "Bronchiolitis Obliterans Syndrome Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Bronchiolitis Obliterans Syndrome (BOS) - ...
Los Angeles, USA, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Bronchiolitis Obliterans Syndrome Pipeline Progresses With Novel, Innovative Therapies Expected to Embrace the Space in the Next Decade With no ...
DelveInsight’s Bronchiolitis Obliterans Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, bronchiolitis obliterans syndrome emerging drugs, market ...
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Bronchiolitis Obliterans Syndrome pipeline constitutes 3+ key companies continuously working towards developing 3+ ...
April 27, 2010 (Chicago, Illinois) — In the 1-year planned interim analysis of the CeMyLungs study, both mycophenolate sodium (MPS) and the mTOR inhibitor everolimus were associated with excellent ...
There are several causes and clinical settings associated with the CB obliterans lesion ( Box 1). Idiopathic obliterative bronchiolitis disorder is rare and has been described in only a few case ...
BOS may be the result of immunologic injury targeting both endothelial and epithelial tissues in the pulmonary system, and such immunologic damage may represent cGVHD, or can be induced and aggravated ...
MILAN and BOSTON, May 8, 2023 /PRNewswire/ -- Zambon, a multinational pharmaceutical company focused on innovating cure and care to improve people's health and the quality of patients' lives, today ...
- BOSTON-3 is an open-label extension study of the pivotal trials in which eligible participants will receive L-CsA-i - BOSTON-4 is a safety and tolerability study of L‑CsA‑i in adults with BOS ...
The Business Research Company's Bronchiolitis Obliterans Syndrome Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 The Business Research Company's Bronchiolitis ...
The main limitation in studying BOS is the lack of reliable diagnostic criteria, as respiratory symptoms are usually nonspecific and may reveal another bronchial disease (BD). At present, the ...
DUBLIN – Zambon SpA is acquiring Breath Therapeutics BV for €140 million (US$155.8 million) up front plus up to €360 million more in regulatory and commercial milestones linked to the progress of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback